Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Design and Synthesis of a New Series of 4-Heteroarylamino-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octanes as α7 Nicotinic Receptor Agonists. 1. Development of Pharmacophore and Early Structure-Activity Relationship.

Cook J, Zusi FC, McDonald IM, King D, Hill MD, Iwuagwu C, Mate RA, Fang H, Zhao R, Wang B, Cutrone J, Ma B, Gao Q, Knox RJ, Matchett M, Gallagher L, Ferrante M, Post-Munson D, Molski T, Easton A, Miller R, Jones K, Digavalli S, Healy F, Lentz K, Benitex Y, Clarke W, Natale J, Siuciak JA, Lodge N, Zaczek R, Denton R, Morgan D, Bristow LJ, Macor JE, Olson RE.

J Med Chem. 2016 Dec 22;59(24):11171-11181. doi: 10.1021/acs.jmedchem.6b01506. Epub 2016 Dec 13.

PMID:
27958732
2.

Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.

Savage MJ, Holder DJ, Wu G, Kaplow J, Siuciak JA, Potter WZ; Foundation for National Institutes of Health (FNIH) Biomarkers Consortium CSF Proteomics Project Team for Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;46(2):431-40. doi: 10.3233/JAD-142778.

3.

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 Sep;9(5):e111-94. doi: 10.1016/j.jalz.2013.05.1769. Epub 2013 Aug 7. Review.

4.

Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease.

Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, Ferm M, Dean RA, Simon AJ, Swenson F, Siuciak JA, Kaplow J, Thambisetty M, Zagouras P, Koroshetz WJ, Wan HI, Trojanowski JQ, Shaw LM; Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project.

Arch Neurol. 2012 Oct;69(10):1310-7.

5.
6.

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Dement. 2012 Feb;8(1 Suppl):S1-68. doi: 10.1016/j.jalz.2011.09.172. Epub 2011 Nov 2. Review.

7.

1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 positive allosteric modulators for the treatment of psychosis.

Zhang L, Brodney MA, Candler J, Doran AC, Duplantier AJ, Efremov IV, Evrard E, Kraus K, Ganong AH, Haas JA, Hanks AN, Jenza K, Lazzaro JT, Maklad N, McCarthy SA, Qian W, Rogers BN, Rottas MD, Schmidt CJ, Siuciak JA, Tingley FD 3rd, Zhang AQ.

J Med Chem. 2011 Mar 24;54(6):1724-39. doi: 10.1021/jm101414h. Epub 2011 Mar 2.

PMID:
21366332
8.

3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimization.

Duplantier AJ, Efremov I, Candler J, Doran AC, Ganong AH, Haas JA, Hanks AN, Kraus KG, Lazzaro JT Jr, Lu J, Maklad N, McCarthy SA, O'Sullivan TJ, Rogers BN, Siuciak JA, Spracklin DK, Zhang L.

Bioorg Med Chem Lett. 2009 May 1;19(9):2524-9. doi: 10.1016/j.bmcl.2009.03.032. Epub 2009 Mar 14.

PMID:
19328692
9.

The role of phosphodiesterases in schizophrenia : therapeutic implications.

Siuciak JA.

CNS Drugs. 2008;22(12):983-93. doi: 10.2165/0023210-200822120-00002. Review.

PMID:
18998737
10.

Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.

Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD 3rd, Williams RD, Verhoest PR, Menniti FS.

J Pharmacol Exp Ther. 2008 May;325(2):681-90. doi: 10.1124/jpet.107.132910. Epub 2008 Feb 20.

PMID:
18287214
11.

Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background.

Siuciak JA, McCarthy SA, Chapin DS, Martin AN, Harms JF, Schmidt CJ.

Neuropharmacology. 2008 Feb;54(2):417-27. Epub 2007 Dec 3.

PMID:
18061215
12.

Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.

Siuciak JA, McCarthy SA, Chapin DS, Martin AN.

Psychopharmacology (Berl). 2008 Mar;197(1):115-26. Epub 2007 Dec 1.

PMID:
18060387
13.

Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia.

Siuciak JA, Strick CA.

Expert Opin Drug Discov. 2007 Jul;2(7):1001-9. doi: 10.1517/17460441.2.7.1001.

PMID:
23484819
14.

Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme.

Siuciak JA, McCarthy SA, Chapin DS, Reed TM, Vorhees CV, Repaske DR.

Neuropharmacology. 2007 Jul;53(1):113-24. Epub 2007 Apr 29.

PMID:
17559891
15.

Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits.

Siuciak JA, McCarthy SA, Martin AN, Chapin DS, Stock J, Nadeau DM, Kantesaria S, Bryce-Pritt D, McLean S.

Psychopharmacology (Berl). 2007 Oct;194(2):185-95. Epub 2007 Jun 10.

PMID:
17558564
16.

Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.

Siuciak JA, Chapin DS, McCarthy SA, Martin AN.

Psychopharmacology (Berl). 2007 Jun;192(3):415-24. Epub 2007 Mar 2.

PMID:
17333137
17.

CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity.

Siuciak JA, Chapin DS, McCarthy SA, Guanowsky V, Brown J, Chiang P, Marala R, Patterson T, Seymour PA, Swick A, Iredale PA.

Neuropharmacology. 2007 Feb;52(2):279-90. Epub 2006 Sep 1.

PMID:
16949622
18.

Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.

Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, Schmidt CJ.

Neuropharmacology. 2006 Aug;51(2):386-96. Epub 2006 Jun 15.

PMID:
16780899
19.

Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function.

Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, Stock JL, McNeish JD, Strick CA, Menniti FS, Schmidt CJ.

Neuropharmacology. 2006 Aug;51(2):374-85. Epub 2006 Jun 12.

PMID:
16769090
20.

The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors.

Siuciak JA, Fujiwara RA.

Psychopharmacology (Berl). 2004 Sep;175(2):163-9. Epub 2004 Feb 25.

PMID:
14985923
21.

Performance of heterozygous brain-derived neurotrophic factor knockout mice on behavioral analogues of anxiety, nociception, and depression.

MacQueen GM, Ramakrishnan K, Croll SD, Siuciak JA, Yu G, Young LT, Fahnestock M.

Behav Neurosci. 2001 Oct;115(5):1145-53.

PMID:
11584927
22.

Hippocampal mossy fiber sprouting induced by chronic electroconvulsive seizures.

Vaidya VA, Siuciak JA, Du F, Duman RS.

Neuroscience. 1999 Mar;89(1):157-66.

PMID:
10051225
23.

Co-infusion with a TrkB-Fc receptor body carrier enhances BDNF distribution in the adult rat brain.

Croll SD, Chesnutt CR, Rudge JS, Acheson A, Ryan TE, Siuciak JA, DiStefano PS, Wiegand SJ, Lindsay RM.

Exp Neurol. 1998 Jul;152(1):20-33.

PMID:
9682009
24.

BDNF induction of tryptophan hydroxylase mRNA levels in the rat brain.

Siuciak JA, Clark MS, Rind HB, Whittemore SR, Russo AF.

J Neurosci Res. 1998 Apr 15;52(2):149-58.

PMID:
9579405
25.

Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the rat.

Cliffer KD, Siuciak JA, Carson SR, Radley HE, Park JS, Lewis DR, Zlotchenko E, Nguyen T, Garcia K, Tonra JR, Stambler N, Cedarbaum JM, Bodine SC, Lindsay RM, DiStefano PS.

Ann Neurol. 1998 Jan;43(1):46-55.

PMID:
9450768
26.

Effects of BDNF infusion on the regulation of TrkB protein and message in adult rat brain.

Frank L, Wiegand SJ, Siuciak JA, Lindsay RM, Rudge JS.

Exp Neurol. 1997 May;145(1):62-70.

PMID:
9184109
27.

Antidepressant-like effect of brain-derived neurotrophic factor (BDNF).

Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM.

Pharmacol Biochem Behav. 1997 Jan;56(1):131-7.

PMID:
8981620
28.

Local infusion of brain-derived neurotrophic factor modifies the firing pattern of dorsal raphé serotonergic neurons.

Celada P, Siuciak JA, Tran TM, Altar CA, Tepper JM.

Brain Res. 1996 Mar 18;712(2):293-8.

PMID:
8814905
29.

BDNF increases monoaminergic activity in rat brain following intracerebroventricular or intraparenchymal administration.

Siuciak JA, Boylan C, Fritsche M, Altar CA, Lindsay RM.

Brain Res. 1996 Feb 26;710(1-2):11-20.

PMID:
8963648
30.

Localization of 2-[125I]iodomelatonin binding sites in visual areas of the turtle brain.

Larson-Prior LJ, Siuciak JA, Dubocovich ML.

Eur J Pharmacol. 1996 Feb 15;297(1-2):181-5.

PMID:
8851181
31.

Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain.

Mamounas LA, Blue ME, Siuciak JA, Altar CA.

J Neurosci. 1995 Dec;15(12):7929-39.

32.

BDNF produces analgesia in the formalin test and modifies neuropeptide levels in rat brain and spinal cord areas associated with nociception.

Siuciak JA, Wong V, Pearsall D, Wiegand SJ, Lindsay RM.

Eur J Neurosci. 1995 Apr 1;7(4):663-70.

PMID:
7620617
33.

In situ hybridization of trkB and trkC receptor mRNA in rat forebrain and association with high-affinity binding of [125I]BDNF, [125I]NT-4/5 and [125I]NT-3.

Altar CA, Siuciak JA, Wright P, Ip NY, Lindsay RM, Wiegand SJ.

Eur J Neurosci. 1994 Sep 1;6(9):1389-405.

PMID:
8000564
34.
35.

Antinociceptive effect of brain-derived neurotrophic factor and neurotrophin-3.

Siuciak JA, Altar CA, Wiegand SJ, Lindsay RM.

Brain Res. 1994 Jan 7;633(1-2):326-30.

PMID:
7511037
36.

Effect of pinealectomy and the light/dark cycle on 2-[125I]iodomelatonin binding in the chick optic tectum.

Siuciak JA, Dubocovich ML.

Cell Mol Neurobiol. 1993 Jun;13(3):193-202.

PMID:
8242684
37.

Optic nerve transection decreases 2-[125I]iodomelatonin binding in the chick optic tectum.

Krause DN, Siuciak JA, Dubocovich ML.

Brain Res. 1992 Sep 11;590(1-2):325-8.

PMID:
1422841
38.
39.
40.

The area of 2-[125I] iodomelatonin binding in the pars tuberalis of the ground squirrel is decreased during hibernation.

Stanton TL, Siuciak JA, Dubocovich ML, Krause DN.

Brain Res. 1991 Aug 23;557(1-2):285-8.

PMID:
1660755
41.

Autoradiographic localization of 2-[125I]iodomelatonin binding sites in the brains of C3H/HeN and C57BL/6J strains of mice.

Siuciak JA, Fang JM, Dubocovich ML.

Eur J Pharmacol. 1990 May 16;180(2-3):387-90.

PMID:
2365011
42.

Antinociceptive effect of intrathecal morphine in tolerant and nontolerant spinal rats.

Siuciak JA, Advokat C.

Pharmacol Biochem Behav. 1989 Nov;34(3):445-52.

PMID:
2623001
43.

Supplemental Content

Loading ...
Support Center